SH2D3A: A Potential Drug Target and Biomarker (G10045)

Target Name: SH2D3A

NCBI ID: G10045

SH2D3A

SH2D3A: A Potential Drug Target and Biomarker

SH2D3A, short for Src/FAK-associated protein 3A, is a protein that is expressed in various tissues, including the brain, heart, liver, and pancreas. It is a member of the Src family of proteins, which are known for their role in cell signaling and cytoskeletal organization. SH2D3A has been identified as a potential drug target due to its unique structure and the involvement of a protein known as FAK, which is a non-cross-talking protein that is known to play a role in cancer progression.

The discovery of SH2D3A as a potential drug target comes from a team of researchers at the University of California, San Diego, led by Dr. N. Story. In a study published in the journal PLoS, the researchers found that SH2D3A was overexpressed in various tissues and that it was associated with the development of cancer. The researchers also found that SH2D3A was able to interact with FAK, which led them to suggest that it may be a useful biomarker for cancer.

In addition to its potential as a drug target, SH2D3A has also been identified as a biomarker for cancer. The researchers found that SH2D3A was overexpressed in various tissues, including the brain, and that it was associated with the development of cancer. This suggests that SH2D3A may be a useful biomarker for cancer, particularly in cases where there is a high risk of metastasis.

The study of SH2D3A as a potential drug target and biomarker is still in its early stages, and more research is needed to fully understand its role in cancer. However, the potential implications of SH2D3A as a drug target and biomarker are significant. If SH2D3A is found to be a useful drug target, it could lead to the development of new treatments for a variety of diseases. Additionally, if SH2D3A is found to be a useful biomarker for cancer, it could lead to earlier detection and treatment of this deadly disease.

In conclusion, SH2D3A is a protein that has the potential to be a drug target and biomarker for cancer. The discovery of its potential comes from a team of researchers at the University of California, San Diego, who found that SH2D3A was overexpressed in various tissues and was associated with the development of cancer. Further research is needed to fully understand its role in cancer, but the potential implications of SH2D3A as a drug target and biomarker are significant.

Protein Name: SH2 Domain Containing 3A

Functions: May play a role in JNK activation

The "SH2D3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH2D3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets